NABRIVA THERAPEUTICS WKN: A2DSZ0 ISIN: IE00BYQMW233 Kürzel: NTY Forum: Aktien Thema: Hauptdiskussion

Ist ja nur ein mögliches Kursziel der Analysten und es wurde entsprechend des RS angepasst. Wichtiger wären hier die richtigen News 🙃

Ich frage mich nur von welchen 2$ die hier schreiben? Der Kurs war nach dem RSplit nie dort und zuvor schon gleich gar nicht.

Na dann mal los 🚀🚀

https://www.streetinsider.com/dr/news.php?id=17688060

Nabriva Therapeutics and Sinovant Sciences Restructure License Agreement for XENLETA for Community-Acquired Bacterial Pneumonia in China http://www.globenewswire.com/news-release/2020/12/07/2140406/0/en/Nabriva-Therapeutics-and-Sinovant-Sciences-Restructure-License-Agreement-for-XENLETA-for-Community-Acquired-Bacterial-Pneumonia-in-China.html - Amended agreement encompasses enhanced manufacturing collaboration and regulatory support -Accelerates milestone payments to Nabriva, including fourth quarter 2020 payment of $1 million

Oh das wäre schön😂

-16% aktuell im Premarket

Nabriva Therapeutics Announces Date of 1-for-10 Reverse Stock Split https://www.globenewswire.com/news-release/2020/12/02/2138276/0/en/Nabriva-Therapeutics-Announces-Date-of-1-for-10-Reverse-Stock-Split.html ...today announced that it will effect a 1-for-10 reverse stock split of its outstanding ordinary shares, which will be effective for trading purposes on the Nasdaq Global Select Market as of the commencement of trading on December 3, 2020.  ...

Nabriva Therapeutics EPS in-line, beats on revenue https://seekingalpha.com/news/3632427-nabriva-therapeutics-eps-in-line-beats-on-revenue • Nabriva Therapeutics (NASDAQ:NBRV): Q3 GAAP EPS of -$0.09 in-line. • Revenue of $1.29M (-81.4% Y/Y) beats by $0.84M. ....

https://www.globenewswire.com/news-release/2020/10/13/2107393/0/en/Nabriva-s-XENLETA-Demonstrates-High-Efficacy-in-Patients-of-Advanced-Age-with-Community-Acquired-Bacterial-Pneumonia-CABP.html

Nabriva Therapeutics (NBRV) Investor Presentation - Slideshow https://seekingalpha.com/article/4374994

https://www.globenewswire.com/news-release/2020/09/10/2091745/0/en/Nabriva-Therapeutics-Granted-New-Technology-Add-On-Payment-for-XENLETA-lefamulin-and-CONTEPO-fosfomycin-by-Centers-for-Medicare-Medicaid-Services.html

Wenn sie den genehmigten Rs durchziehen könnte es klappen.

Können wir 2 Euro dieses Jahr noch erwarten ?

Nabriva files for $150M mixed shelf https://seekingalpha.com/news/3610757

Nabriva Therapeutics Plc (NBRV) CEO Ted Schroeder on Q2 2020 Results - Earnings Call Transcript https://seekingalpha.com/article/4366661